Intec Pharma, which is developing an improved delivery method of carbidopa/levodopa for Parkinson's disease, raised $30 million by offering 5 million shares at $6. In early trading on the Nasdaq (symbol NTEC), the stock was trading slightly below $6, down 3-5%. Intec Pharma previously traded on the Tel Aviv Stock Exchange and initially filed confidentially for a US listing on 4/7/2014. Maxim Group LLC and Roth Capital acted as lead managers on the deal.
